Natco Pharma raises eGenesis stake to $16.7 million
In short
Natco Pharma has raised its investment in US biotech eGenesis to $16.7 million from $14 million. The company is backing research on gene-edited pig organs for human transplants.
This matters because it shows Natco is putting more money into a long-shot biotech project. The report does not say when the increase happened or what return Natco expects.
What the reporting says
Natco Pharma raised its investment in US biotech eGenesis to $16.7 million from $14 million, backing research on gene-edited pig organs for human transplants. The reporting says the move supports organ-replacement research, but it does not state the size of Natco’s stake, the timing of the increase, or any expected financial return. The immediate market or regulatory impact is not stated.
Why it matters
Natco Pharma increased its investment in US biotech eGenesis to $16.7 million from $14 million, according to the summary. The move supports research into gene-edited pig organs for human transplants, which puts Natco alongside a high-risk, potentially high-reward biotech program. The available reporting does not state the size of Natco’s ownership position, the timing of the change, or any commercial milestone.